Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Paralleled to the pharmaceutical market, the vaccine market is relatively small and concentrated on both supply and demand sides. It is highly regulated and largely reliant on on public purchasers and donor policies. The vaccine market has very distinct features, which increase the complexity of assessing and understanding pricing and procurement. It is made up of individual markets for individual vaccines or vaccine types, each with their own specificities, particularly on the supply side. The main performers on the demand side of the vaccine industry are governments of industrialized and developing countries, pooled procurement agencies, the private sector, and the various regulatory and advisory bodies overseeing vaccine quality and safety. According to the WHO, high Income Countries (HICs) constitute 82% of global vaccine sales in terms of value, corresponding to about 20% of the annual volume of vaccines sold. Not only do HICs pay higher prices, they are more likely to implement newer vaccines.
As the COVID-19 pandemic headways, pharmaceutical and biotechnology companies are swelling their efforts to find a cure for the disease. In just a few weeks, scientists have found a list of molecules that target COVID-19. The growth of the COVID vaccines market is attributed majorly to the rising number of persons infected with COVID-19 and swelling funding for vaccine development. The speed and scale of the R&D response to the COVID-19 outbreak is unprecedented in human history, with billions of dollars being spent and committed in pursuit of drugs, vaccines, and diagnostics for the virus. Currently, there are more than 150 vaccines in the pipeline, and 200 drug candidates. On diagnostics, beyond the RT-PCR5 and classic lateral-flow immunoassays already in use for many viral and antibody tests, new expertise such as CRISPR6 have already been granted emergency-use authorization by the US Food and Drug Administration.
The past few months have seen the introduction of numerous trials in an effort to find therapies and vaccines, with some challenges from studies that are too small in size, or not randomized or controlled. As of early May, more than 1,700 trials are in progress targeting COVID-19 and related complications. More of these are randomized and controlled clinical studies and some are starting read out results, providing evidence to support new approaches to avert and manage COVID-19 infection and associated complications. The exclusive COVID-19 Impact Analysis report by Axiom MRC explores the outbreak of COVID-19, its impact on the global and regional economies, and its implications on the cosmetic sector. The report studies the effect of the pandemic on the global economy by evaluating factors like consumption, GDP, business investment, key players marketing strategies, key supply and demand-side factors, epidemiological swing factors, inventory, and governmental policies & decisions.
The global vaccine industry is analysed based on vaccine type, valance type, route of administration, indication type, patient type, distribution channel and geography. Different type of vaccines studied in this vertical are live attenuated, inactivated & subunit, conjugate, toxoid and recombinant vaccines. Vaccines are categorized based upon their immunity against the number of pathogens such as monovalent and multivalent vaccines. They are designed to administer orally, can be injected and also, administered through intranasal spray application. They are often injected intramuscularly, subcutaneously and intradermal. Vaccination is carried out for indications such as hepatitis, polio, varicella, diphtheria, pertussis, human papilloma virus, tetanus and influenza. Also, it is used against rotavirus, measles, mumps, and rubella, meningococcal & pneumococcal diseases. They are offered to pediatrics and adults. Globally, vaccines are distributed to institutional sales, hospital pharmacies, retail pharmacies and clinics. Global vaccine market is analysed across the various regions geographically including North America, Europe, Asia Pacific and rest of world.
Pivotal market performers in the global vaccine market are AstraZeneca, GlaxoSmithKline plc, Sanofi Pasteur SA, Pfizer, Inc., Panacea Biotec, Merck & Co., Inc., Janssen Pharmaceutical Company (Part of Johnson & Johnson),Serum Institute of India Ltd, Emergent Bio Solutions Inc.,CSL, Bavarian Nordic, IBSS BIOMED S.A., Novavax AB, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma, Biological E and Daiichi Sankyo Company.
The repercussion of the COVID-19 necessitates a speculative future for economies and industries. Amongst continuous and constant developments, Axiom team of experts will bring to you timely updates about the Global Economic Impact of COVID-19.
Why to buy this report:
GET CUSTOMIZED MARKET DATA